Joseph A. Sparano, MD, on Multimodal AI Models for Predicting Breast Cancer Recurrence
SABCS 2025
Joseph A. Sparano, MD, of the Icahn School of Medicine at Mount Sinai, discusses the performance of experimental multimodal artificial intelligence (AI) models integrating clinical, molecular, and histopathologic features to provide prognostic information for early and late recurrence using primary tumor samples and clinical data from participants in the TAILORx trial (Abstract GS1-08).
The ASCO Post Staff
Jame Abraham, MD, FACP, discusses follow-up data from the DESTINY Breast-05 and DESTINY Breast-11 trials of fam-trastuzumab deruxtecan-nki (T-DXd) for HER2-positive early breast cancer. DESTINY Breast-05 examined the agent given postneoadjuvantly, while DESTINY Breast-11 evaluated the agent in a neoadjuvant setting. Dr. Abraham is Enterprise Chair of the Department of Hematology & Medical Oncology at Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.
The ASCO Post Staff
Jame Abraham, MD, FACP, puts findings from several trials in HER2-positive breast cancer into context, including HER2CLIMB, which investigated tucatinib, trastuzumab, and capecitabine in pretreated patients with metastatic disease; DESTINY Breast-09, which evaluated fam-trastuzumab deruxtecan-nki (T-DXd) plus pertuzumab in patients with advanced or metastatic disease who had received no previous chemotherapy or HER2-directed therapy for metastatic disease; and PATINA, which looked at the addition of palbociclib to maintenance anti-HER2 and endocrine therapies in hormone receptor–positive disease. Dr. Abraham is Enterprise Chair of the Department of Hematology & Medical Oncology at Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.
Jame Abraham, MD, FACP, discusses the global, randomized lidERA Breast Cancer trial. Results from lidERA position giredestrant as a potential new standard of care for patients with estrogen receptor (ER)-positive, HER2-negative stage I to III early breast cancer, marking the first phase III trial to demonstrate a benefit with an oral selective estrogen receptor degrader (SERD) in this setting. Dr. Abraham is Enterprise Chair of the Department of Hematology & Medical Oncology at Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.
